Literature DB >> 26613945

High-density lipoprotein mimetics: promises and challenges.

Dmitri Sviridov1, Alan T Remaley2.   

Abstract

The concept of lipoprotein mimetics was developed and extensively tested in the last three decades. Most lipoprotein mimetics were designed to recreate one or several functions of high-density lipoprotein (HDL) in the context of cardiovascular disease; however, the application of this approach is much broader. Lipoprotein mimetics should not just be seen as a set of compounds aimed at replenishing a deficiency or dysfunctionality of individual elements of lipoprotein metabolism but rather as a designer concept with remarkable flexibility and numerous applications in medicine and biology. In the present review, we discuss the fundamental design principles used to create lipoprotein mimetics, mechanisms of their action, medical indications and efficacy in animal models and human studies.
© 2015 Authors; published by Portland Press Limited.

Entities:  

Keywords:  apolipoproteins; atherosclerosis; cholesterol metabolism; lipoprotein metabolism; peptides

Mesh:

Substances:

Year:  2015        PMID: 26613945      PMCID: PMC5606976          DOI: 10.1042/BJ20150832

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  105 in total

1.  The apolipoprotein A-I mimetic peptide ETC-642 exhibits anti-inflammatory properties that are comparable to high density lipoproteins.

Authors:  Belinda A Di Bartolo; Stephen J Nicholls; Shisan Bao; Kerry-Anne Rye; Alison K Heather; Philip J Barter; Christina Bursill
Journal:  Atherosclerosis       Date:  2011-04-16       Impact factor: 5.162

2.  Enhancement by LDL of transfer of L-4F and oxidized lipids to HDL in C57BL/6J mice and human plasma.

Authors:  David Meriwether; Satoshi Imaizumi; Victor Grijalva; Greg Hough; Ladan Vakili; G M Anantharamaiah; Robin Farias-Eisner; Mohamad Navab; Alan M Fogelman; Srinivasa T Reddy; Ishaiahu Shechter
Journal:  J Lipid Res       Date:  2011-07-29       Impact factor: 5.922

3.  D-4F, an apolipoprotein A-I mimetic peptide, inhibits the inflammatory response induced by influenza A infection of human type II pneumocytes.

Authors:  Brian J Van Lenten; Alan C Wagner; Mohamad Navab; G M Anantharamaiah; Eric Ka-Wai Hui; Debi P Nayak; Alan M Fogelman
Journal:  Circulation       Date:  2004-11-08       Impact factor: 29.690

4.  The apolipoprotein A-I mimetic peptide 4F prevents defects in vascular function in endotoxemic rats.

Authors:  Lijun Dai; Geeta Datta; Zhenghao Zhang; Himanshu Gupta; Rakesh Patel; Jaideep Honavar; Sarika Modi; J Michael Wyss; Mayakonda Palgunachari; G M Anantharamaiah; C Roger White
Journal:  J Lipid Res       Date:  2010-05-22       Impact factor: 5.922

5.  L-4F, an apolipoprotein A-1 mimetic, dramatically improves vasodilation in hypercholesterolemia and sickle cell disease.

Authors:  Jingsong Ou; Zhijun Ou; Deron W Jones; Sandra Holzhauer; Ossama A Hatoum; Allan W Ackerman; Dorothee W Weihrauch; David D Gutterman; Karen Guice; Keith T Oldham; Cheryl A Hillery; Kirkwood A Pritchard
Journal:  Circulation       Date:  2003-05-05       Impact factor: 29.690

6.  Apolipoprotein E derived HDL mimetic peptide ATI-5261 promotes nascent HDL formation and reverse cholesterol transport in vitro.

Authors:  Anouar Hafiane; John K Bielicki; Jan O Johansson; Jacques Genest
Journal:  Biochim Biophys Acta       Date:  2014-08-01

7.  Trimerization of apolipoprotein A-I retards plasma clearance and preserves antiatherosclerotic properties.

Authors:  Jonas Heilskov Graversen; Jacob Marsvin Laurberg; Mikkel Holmen Andersen; Erling Falk; John Nieland; Jesper Christensen; Michael Etzerodt; Hans Christian Thøgersen; Søren Kragh Moestrup
Journal:  J Cardiovasc Pharmacol       Date:  2008-02       Impact factor: 3.105

8.  Inflammation/oxidation in chronic rejection: apolipoprotein a-i mimetic peptide reduces chronic rejection of transplanted hearts.

Authors:  George R Hsieh; Gabriel T Schnickel; Consuelo Garcia; Ali Shefizadeh; Michael C Fishbein; Abbas Ardehali
Journal:  Transplantation       Date:  2007-07-27       Impact factor: 4.939

9.  An apoA-I mimetic peptide containing a proline residue has greater in vivo HDL binding and anti-inflammatory ability than the 4F peptide.

Authors:  Geoffrey D Wool; Tomas Vaisar; Catherine A Reardon; Godfrey S Getz
Journal:  J Lipid Res       Date:  2009-05-11       Impact factor: 5.922

10.  MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins.

Authors:  Kasey C Vickers; Brian T Palmisano; Bassem M Shoucri; Robert D Shamburek; Alan T Remaley
Journal:  Nat Cell Biol       Date:  2011-03-20       Impact factor: 28.824

View more
  9 in total

Review 1.  Reconstituted Discoidal High-Density Lipoproteins: Bioinspired Nanodiscs with Many Unexpected Applications.

Authors:  Maki Tsujita; Anna Wolska; Daniel A P Gutmann; Alan T Remaley
Journal:  Curr Atheroscler Rep       Date:  2018-11-05       Impact factor: 5.113

2.  Apo A-I (Apolipoprotein A-I) Vascular Gene Therapy Provides Durable Protection Against Atherosclerosis in Hyperlipidemic Rabbits.

Authors:  Bradley K Wacker; Nagadhara Dronadula; Lianxiang Bi; Alexis Stamatikos; David A Dichek
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-11-09       Impact factor: 8.311

3.  Apolipoprotein A-I Mimetic Peptides: Discordance Between In Vitro and In Vivo Properties-Brief Report.

Authors:  Michael Ditiatkovski; Jonatan Palsson; Jaye Chin-Dusting; Alan T Remaley; Dmitri Sviridov
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-05-18       Impact factor: 8.311

4.  HDL Mimetic Peptides.

Authors:  Jie Chen; Jiewen Liu; Baoqi Yu
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

5.  Intravenous toxicity and toxicokinetics of an HDL mimetic, Fx-5A peptide complex, in cynomolgus monkeys.

Authors:  Mohammed Bourdi; Marcelo Amar; Alan T Remaley; Pramod S Terse
Journal:  Regul Toxicol Pharmacol       Date:  2018-10-22       Impact factor: 3.271

6.  Decreased high density lipoprotein cholesterol is an independent predictor for persistent organ failure, pancreatic necrosis and mortality in acute pancreatitis.

Authors:  Yushun Zhang; Feng Guo; Shoukang Li; Feiyang Wang; Zibo Meng; Jingyuan Zhao; Zhiqiang Liu; Bo Wang; Ping Fan; Chunyou Wang; Heshui Wu
Journal:  Sci Rep       Date:  2017-08-14       Impact factor: 4.379

Review 7.  The Role of High-Density Lipoproteins in Diabetes and Its Vascular Complications.

Authors:  Nathan K P Wong; Stephen J Nicholls; Joanne T M Tan; Christina A Bursill
Journal:  Int J Mol Sci       Date:  2018-06-05       Impact factor: 5.923

8.  Major Lipids and Future Risk of Pneumonia: 20-Year Observation of the Atherosclerosis Risk in Communities (ARIC) Study Cohort.

Authors:  Sangmee Sharon Bae; L Cindy Chang; Sharon Stein Merkin; David Elashoff; Junichi Ishigami; Kunihiro Matsushita; Christina Charles-Schoeman
Journal:  Am J Med       Date:  2020-08-16       Impact factor: 4.965

9.  HDL in the 21st Century: A Multifunctional Roadmap for Future HDL Research.

Authors:  Anand Rohatgi; Marit Westerterp; Arnold von Eckardstein; Alan Remaley; Kerry-Anne Rye
Journal:  Circulation       Date:  2021-06-07       Impact factor: 39.918

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.